Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

25%

Ph phase_4

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

1(25.0%)

Phase 4Post-market surveillance

3(75.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Other(1)

Detailed Status

Completed3

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 21 (25.0%)

Phase 43 (75.0%)

Trials by Status

completed375%

unknown125%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_4

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent

NCT02660047

completedphase_4

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

NCT01761318

unknownphase_2

Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?

NCT01845259

completedphase_4

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

NCT01744236

Clinical Trials (4)

Showing 4 of 4 trials

NCT02660047Phase 4

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent

Completed

NCT01761318Phase 4

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

Completed

NCT01845259Phase 2

Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?

Unknown

NCT01744236Phase 4

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4